Waldemar Debinski to Ephrin-A1
This is a "connection" page, showing publications Waldemar Debinski has written about Ephrin-A1.
Connection Strength
2.813
-
Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem. 2013 Jun 21; 288(25):18448-57.
Score: 0.461
-
Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012 Aug; 32(16):3253-64.
Score: 0.433
-
Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012 Apr 20; 287(17):14012-22.
Score: 0.424
-
Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol. 2012 Feb; 23(1):109-15.
Score: 0.414
-
Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008 Dec; 6(12):1795-806.
Score: 0.339
-
Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. . 2007 Dec; 6(12 Pt 1):3208-18.
Score: 0.316
-
Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005 Oct; 3(10):541-51.
Score: 0.272
-
Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J. 2017 Jul 25; 113(2):472-480.
Score: 0.154